Eva L. Feldman, MD, PhD

Founder & Director

Eva Feldman, M.D., Ph.D., the University of Michigan (U-M) James W. Albers Distinguished University Professor and Russell N. DeJong Professor of Neurology at Michigan Medicine, is known internationally for her groundbreaking research and leadership across neurological disorders like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease and related dementias, as well as the effect diet and obesity have on peripheral nerves (neuropathy) and brain health. She is also investigating the impact of environmental exposures on the nervous system.

photo of Dr. Eva Feldman

Dr. Feldman’s forward-thinking approach has transformed how these devastating conditions are diagnosed, treated, and prevented by realizing the necessity of a collaborative multidisciplinary approach — such as discovering a link between diabetes and Alzheimer’s disease, and creating a stem cell therapy that led to the first human clinical trial for ALS patients. Her career has also been punctuated by dynamic discovery, such as her identification of the connection of ALS to exposure to environmental toxins. Her efforts focused on peripheral neuropathy have led to a change in practice guidelines for early diagnosis of neuropathy in individuals with prediabetes, and she identified the role lipids, or fats, play in the development of neuropathy in type 2 diabetes, providing evidence for new guidelines by the American Diabetes Association. Dr. Feldman has been at the forefront of studying the neurological impact of COVID-19 on persons with diabetes. She has authored more than 530 scientific articles, 74 book chapters, and five books on neurological diseases, their mechanisms, and potential therapies. She has been continuously funded by the NIH for over 30 years and is currently the principal or co-investigator of numerous clinical trials and grants, including nine NIH grants.  

Since joining the U-M faculty in 1988 as a clinician-scientist in the Department of Neurology’s neuromuscular division, her contributions to training and research are innumerable. A dedicated mentor and educator, she has influenced the development of generations of physicians and scientists — ten of whom received Ph.D. degrees under her. She has trained over 65 postdoctoral neuroscience fellows in her laboratory and well over 60 neurologists specializing in neuromuscular diseases. She established the NeuroNetwork for Emerging Therapies where she directs more than 30 scientists exploring neurological diseases of all kinds and from all angles and has directed the ALS Center of Excellence since 2001. In 2007, she launched and led U-M’s A. Alfred Taubman Medical Research Institute, developed its Emerging Scholar Program, and organized its Consortium of Stem Cell Therapies. She also contributed to the framework for U-M’s Center for RNA Biomedicine. She has served as a U-M ambassador, speaking to local and national agencies and governmental bodies. She is the only individual to receive both U-M’s Early Distinguished Career Award and its Distinguished Faculty Achievement Award and the first woman to receive its Distinguished Alumnus Achievement Award. In 2022, Dr. Feldman was awarded the University of Michigan Distinguished University Professorship, U-M's highest faculty honor.

photo of Dr. Eva Feldman and A. Alfred Taubman
Dr. Feldman & A. Alfred Taubman

Dr. Feldman is a past president of the American Neurological Association and the Peripheral Nerve Society. She has been elected to the Johns Hopkins Society of Scholars, the National Academy of Medicine, the Association of American Physicians, and the American Association for the Advancement of Science Fellows. She chaired the National Academy of Medicine Neurology and Psychiatry Section from 2020-2022, and was appointed to the NAM's (governing and oversight) Council in 2023. She was named one of the 2011 Michiganians of the Year by the Detroit News and has been honored by Crain’s Detroit Business, the Society for Neuroscience, and the Endocrine Society, among others. She was also named an honorary fellow of the American Neurological Association. In 2021, she received the NIH Director’s Transformative Research Award as the leader of an interdisciplinary team focused on using science to make ALS a preventable disease. She received the Raymond D. Adams Lectureship from the American Neurological Association that same year. In 2022, she became the first female recipient of the Robert S. Schwab Award in its 25-year history from the American Clinical Neurophysiological Society. Dr. Feldman sits on numerous editorial boards of well-respected medical journals, such as JAMA Neurology and Lancet Neurology, is editor of the Contemporary Neurology series, and serves as the neurology consultant for NIH’s large studies on children and adults with type 1 diabetes.

Dr. Feldman sees some of her most significant accomplishments as guiding and supporting the future of medical science through mentoring and inspiring the next generation of scientists and physicians. She received the Society for Neuroscience Bernice Grafstein Award for Outstanding Accomplishments in Mentoring in 2016, and the Michigan Institute for Clinical & Health Research Institutional (MICHR) Distinguished Clinical and Translational Research Mentor Award in 2019.

Dr. Feldman received her M.D. and Ph.D. — as a Rackham Scholar — in neuroscience from the University of Michigan. She completed her neurology residency at Johns Hopkins, where she served as chief resident and was the first neurologist to receive the Johns Hopkins Award for Medical Teaching and Excellence. Before joining the neurology faculty, Dr. Feldman completed her training at U-M as a neuromuscular disorders fellow.